Proteon Therapeutics Appoints Jennifer Panagoulias as Vice President of Regulatory Affairs
September 01, 2015 07:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Announces Second Quarter 2015 Financial Results
August 13, 2015 17:15 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease
August 13, 2015 16:45 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Initiates Second Phase 3 Clinical Study of Investigational Drug Vonapanitase
August 12, 2015 07:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Appoints Scott Canute to Its Board of Directors
July 22, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., July 22, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Announces Addition to Russell 2000 Index
June 29, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 29, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at the JMP Securities Life Science Conference June 24th
June 17, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 17, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
June 08, 2015 21:12 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...
Proteon Therapeutics Appoints Scott Toner as Senior Vice President of Marketing
June 02, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at Upcoming ERA-EDTA Annual Congress
May 22, 2015 07:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 22, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...